Ā | All | China | South Asia | East Asia | North Africa | Middle East | Latin America | Russia |
---|---|---|---|---|---|---|---|---|
Patients with macrovascular complications | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
RAS blocker, n (%) | 13,910 (78.1) | 1,303 (55.6) | 3,771 (76.3) | 1,992 (74.2) | 778 (79.5) | 3,719 (86.6) | 285 (85.1) | 2,062 (92.6) |
Aspirin, n (%) | 13,995 (78.6) | 1,644 (70.2) | 3,784 (76.6) | 1,866 (69.5) | 801 (81.8) | 3,973 (92.5) | 252 (75.2) | 1,675 (75.2) |
Statins, n (%) | 11,958 (67.2) | 1,139 (48.6) | 3,057 (61.9) | 1,846 (68.8) | 715 (73.0) | 3,710 (86.4) | 189 (56.4) | 1,302 (58.5) |
Patients with microvascular complications | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
RAS blocker, n (%) | 21,884 (62.6) | 2,268 (41.5) | 4,792 (58.5) | 3,465 (61.7) | 1,557 (65.0) | 6,907 (70.1) | 499 (69.8) | 2,396 (87.3) |
Aspirin, n (%) | 22,207 (63.5) | 2,704 (49.5) | 4,958 (60.6) | 2,698 (48.0) | 1,598 (66.7) | 7,922 (80.5) | 427 (59.7) | 1,900 (69.2) |
Statins, n (%) | 19,709 (56.4) | 1,856 (33.9) | 4,325 (52.8) | 3,133 (55.8) | 1,288 (53.7) | 7,323 (74.4) | 312 (43.6) | 1,472 (53.6) |